Inflammation and heart disease in men: What to test and what to do next

Chronic, low-grade inflammation is a proven risk factor for atherosclerotic heart disease, and simple blood tests can detect it before symptoms appear. If your cholesterol looks “fine” but your family history, waistline, or energy say otherwise, inflammation may be the missing piece in your heart risk assessment.

Key takeaways

• Inflammatory risk-enhancing factors (including high-sensitivity C-reactive protein) can refine ASCVD risk assessment beyond a standard lipid panel in selected men. ^[1]
• When measured away from acute illness, hsCRP <1 mg/L suggests lower risk, 1 to 3 mg/L suggests average risk, and >3 mg/L suggests higher risk; confirm persistence with repeat testing. ^[2]
• Lipoprotein(a) is largely genetic, and an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L) is a risk-enhancing factor ^[1]; because levels change little over life, many men only need it checked once. ^[3]
• A higher triglyceride-to-HDL cholesterol ratio often travels with insulin resistance and visceral fat, which commonly overlap with chronic inflammation and higher cardiometabolic risk.
• Marine omega-3s (EPA+DHA) have clinical-trial evidence for modestly lowering CRP in some populations, and curcumin has human evidence for lowering inflammatory markers in some settings; use them to support (not replace) lifestyle changes and guideline-based care. ^{[4] [5]}

Why inflammation is a heart disease risk factor for men

As Libby’s 2002 review in Nature explains, inflammation links high cholesterol to atherosclerotic cardiovascular disease (ASCVD): white blood cells recruited into the artery wall help build plaque, and inflammatory pathways promote the clotting that causes heart attacks and most strokes. ^[6] ASCVD is heart and blood vessel disease caused by plaque that narrows and stiffens arteries.

According to the 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease, risk-enhancing factors can help decide whether to start a statin in adults whose estimated 10-year risk is borderline or intermediate. ^[1] The list includes persistently elevated hsCRP (2.0 mg/L or higher), chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, metabolic syndrome, and a family history of premature ASCVD. ^[1]

Chronic low-grade inflammation usually causes no symptoms of its own, so it is found by testing. According to the 2003 statement from the Centers for Disease Control and Prevention and the American Heart Association, hsCRP is not recommended for screening the whole adult population; it is considered reasonable, at the clinician’s discretion, in adults at intermediate risk (an estimated 10 to 20 percent 10-year risk of coronary heart disease), where the result can change further evaluation or treatment. ^[2]

How inflammation drives plaque and heart attacks

Inflammation injures the endothelium

The endothelium is the inner lining of blood vessels. In early atherosclerosis, activated endothelial cells capture passing white blood cells, which move into the artery wall and release pro-inflammatory cytokines that drive plaque formation. ^[6]

The same lining controls blood flow to working muscles and to the penis, so vascular damage is not limited to the heart, and good fitness does not rule it out when inflammation stays high for years.

Inflammation helps plaque form and then makes it unstable

Atherosclerosis involves the immune system as much as cholesterol. Plaque is a fatty, fibrous buildup in the artery wall. Inflammation helps plaque form and can weaken the fibrous cap that covers it, making rupture more likely. ^[6]

When a plaque ruptures, its contents meet the blood and trigger a clot. A clot that blocks a coronary artery causes a heart attack; one that cuts off blood flow to the brain causes an ischemic stroke. ^[6]

Inflammation raises clot tendency

Inflammatory pathways also push the blood toward a prothrombotic state, meaning a higher tendency to form clots, which is one reason inflammation is tied to both heart attack and ischemic stroke. ^[6]

This helps explain why two men with similar LDL cholesterol can carry different risk. The CDC and AHA statement describes hsCRP as an independent marker of cardiovascular risk, meaning it adds information beyond cholesterol levels. ^[2]

Why ratios and particle counts add information

One biomarker in isolation can miss patterns. Apolipoprotein B (ApoB) reflects the number of atherogenic lipoprotein particles, and the 2019 prevention guideline lists ApoB of 130 mg/dL or higher as a risk-enhancing factor. ^[1]

Small, dense LDL particles are the hallmark of a pattern called the atherogenic lipoprotein phenotype, which also includes more triglyceride-rich remnant particles, low HDL cholesterol, and insulin resistance. These smaller particles enter the artery wall more readily, bind more tightly to it, and oxidize more easily. ^[7] Some clinicians use a low LDL cholesterol to ApoB ratio as a rough, indirect clue to smaller particles.

Triglycerides divided by HDL cholesterol is another rough proxy for the same insulin-resistant pattern, best read alongside waist circumference, blood pressure, and fasting glucose.

What fuels chronic inflammation in men

Chronic inflammation rarely has one cause. It usually comes from several inputs that keep the immune system slightly activated for years, and the practical goal is to find the largest drivers you can change.

• Visceral fat and insulin resistance. Visceral fat is fat stored around internal organs. In obesity, fat tissue and the liver fill with activated macrophages that release pro-inflammatory cytokines, and these cytokines blunt insulin signaling in fat, muscle, and liver, contributing to insulin resistance and metabolic syndrome. ^[8]
• Smoking. Cigarette smoke drives oxidative stress, inflammatory cytokine release, and endothelial dysfunction, speeds plaque development, and activates platelets and clotting. Many of these clotting changes reverse quickly after quitting. ^[9]
• Poor sleep. Ongoing sleep disruption is associated with higher blood pressure, impaired glucose control, and inflammatory activation over time, and it also affects appetite and training recovery.
• Chronic stress. Social and psychological stress can up-regulate inflammatory signaling. One review proposes this pathway as a link between stress, depression, and conditions including cardiovascular disease and metabolic syndrome, though it is presented as a theoretical model. ^[10]
• Autoimmune and inflammatory diseases. Rheumatoid arthritis, the most common inflammatory arthritis, is an immune-mediated disease whose effects extend beyond the joints to blood vessels and metabolism. ^[11] The 2019 prevention guideline counts chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, and HIV as cardiovascular risk-enhancing factors. ^[1]

These links are real, but they do not form a perfect checklist. hsCRP is sensitive but not specific: infection, injury, and other inflammatory conditions raise it, not only arterial disease, so a single result needs context and often a repeat test. ^[2]

Signs and lab signals to watch

Most men with chronic inflammation feel nothing specific. What shows up instead is a slow drift in health markers and vague changes that have many possible causes.

• Signals worth a closer look: rising waist circumference, higher fasting triglycerides, and higher blood pressure. Persistent low energy, slower training recovery, or brain fog are nonspecific but can prompt a broader workup.
• Situations where inflammation testing is especially useful: family history of early heart disease, normal LDL cholesterol with abnormal triglycerides, or cardiovascular events despite standard therapy.

The CDC and AHA statement identifies high-sensitivity C-reactive protein (hsCRP) as the inflammatory marker best suited to clinical practice, given its stability and the availability of standardized assays. ^[2] CRP is made by the liver in response to inflammation, and the high-sensitivity test detects smaller increases that routine CRP may miss. ^[2]

• <1.0 mg/L: lower risk ^[2]
• 1.0 to 3.0 mg/L: average risk ^[2]
• >3.0 mg/L: higher risk when persistent ^[2]

Test when you are well, not during or right after an infection or injury. The statement recommends averaging two measurements taken about two weeks apart, and a result above 10 mg/L should prompt a search for an infection or other inflammatory cause and a repeat test. ^[2]

Lipoprotein(a) is an inherited LDL-like particle linked to atherosclerotic risk. The 2019 prevention guideline treats Lp(a) of 50 mg/dL or higher (125 nmol/L or higher) as a risk-enhancing factor. ^[1] Because levels are mainly genetically determined, the 2019 ESC/EAS guidelines on dyslipidemia recommend considering an Lp(a) measurement at least once in every adult’s lifetime. ^[3]

Remnant cholesterol is cholesterol carried in triglyceride-rich lipoproteins, such as VLDL remnants. A 2013 Mendelian randomization study by Varbo and colleagues in the Journal of the American College of Cardiology genotyped 73,513 people from Copenhagen and estimated that a genetically determined 1 mmol/L (39 mg/dL) rise in nonfasting remnant cholesterol carried a 2.8-fold causal risk of ischemic heart disease, independent of low HDL cholesterol. ^[12] The authors noted that other effects of the gene variants could not be fully excluded and called for confirmation in randomized trials. ^[12]

You can estimate remnant cholesterol from a standard lipid panel: total cholesterol minus LDL cholesterol minus HDL cholesterol.

White blood cell patterns and RDW can add context. A complete blood count (CBC) with differential counts each type of white blood cell, and a mildly high count has many nonmalignant causes, including smoking, obesity, and chronic inflammatory conditions, as well as infection, exercise, and stress. ^[13] RDW (red blood cell distribution width) reflects variation in red blood cell size and carries prognostic information in several conditions, although it is not a specific marker of inflammation. ^[14] Some clinicians also look at ratios from the CBC (such as neutrophils relative to lymphocytes) as a general inflammation signal, but cutoffs are not standardized and results should be interpreted in context.

What to do about inflammation and heart disease risk

The plan does not depend on one supplement or one number. It has three steps: test, address the largest drivers, and retest to see whether the numbers move.

1. Test the right markers, at the right time. Ask your clinician for a lipid panel with hsCRP and lipoprotein(a), and consider ApoB and a CBC with differential for a broader picture. If you also have symptoms that suggest hypogonadism (consistently low libido, erectile dysfunction, infertility concerns, or unexplained fatigue), discuss morning total testosterone testing. The Endocrine Society’s 2018 guideline recommends a fasting morning total testosterone measured with an accurate assay and repeated to confirm a low result, a free testosterone by equilibrium dialysis or an accurate formula when total testosterone is borderline or SHBG is abnormal, and LH and FSH to distinguish testicular causes from problems in the brain’s signaling. ^[15] The 2018 AUA guideline uses a total testosterone below 300 ng/dL, confirmed on two early morning draws and combined with symptoms, as a reasonable diagnostic cut-off. ^[16]
2. Address the main drivers first. According to the 2019 ACC/AHA guideline, guideline-based prevention rests on at least 150 minutes of moderate (or 75 minutes of vigorous) physical activity per week, weight loss for men with overweight or obesity, and a minimally processed eating pattern that emphasizes vegetables, fruits, legumes, nuts, whole grains, and fish while limiting processed meats and refined carbohydrates. ^[1] Sleep deserves attention as well. If you smoke, quitting comes first, and many of the clotting changes caused by cigarette smoke reverse quickly after cessation. ^[9]
3. Escalate with a clinician, then monitor. If risk stays high after lifestyle work, your clinician may discuss a statin. In the JUPITER trial, published in the New England Journal of Medicine in 2008, 17,802 apparently healthy adults with LDL cholesterol below 130 mg/dL and hsCRP of 2.0 mg/L or higher received rosuvastatin 20 mg daily or placebo; over a median of 1.9 years, rosuvastatin lowered major cardiovascular events by 44 percent (hazard ratio 0.56), along with a 50 percent drop in LDL cholesterol, a 37 percent drop in hsCRP, and more physician-reported diabetes. ^[17] If testing confirms testosterone deficiency with consistent symptoms, the Endocrine Society guideline recommends treatment only after discussing benefits and risks, with monitoring of testosterone and hematocrit, and recommends against testosterone therapy in men planning fertility in the near term. ^[15] Men who want to preserve fertility can discuss treatments that stimulate the testes’ own production; enclomiphene is one such option.

Testosterone and cardiovascular risk

Testosterone is not an inflammation marker, but symptoms with a consistently low testosterone level often coexist with visceral fat gain, insulin resistance, and reduced exercise capacity, which can indirectly worsen cardiometabolic risk. Testing is most useful when it feeds a broader plan: sleep, weight, alcohol intake, medication review, and evaluation for reversible causes. Testosterone therapy is not a treatment for cardiovascular risk.

Diagnosis and treatment are separate decisions. The Endocrine Society guideline recommends diagnosing hypogonadism only in men who have symptoms and signs of testosterone deficiency together with unequivocally and consistently low testosterone, so a single low result is not a diagnosis. ^[15]

Targeted supplements. Supplements can be adjuncts when your clinician agrees they fit your labs and medications. A 2014 meta-analysis in PLoS One by Li and colleagues pooled 68 randomized trials with 4,601 participants and found that marine omega-3 supplements lowered CRP, IL-6, and TNF-α; longer use gave larger effects, and the effect weakened in people with a body mass index above 30. ^[4] A 2017 review by Hewlings and Kalman describes anti-inflammatory effects of curcumin but notes that curcumin taken alone is poorly absorbed and quickly eliminated, so results depend on the formulation. ^[5] Neither replaces sleep, training consistency, and nutrition quality.

For men whose symptoms point to low testosterone, Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs already done, interpreted by licensed providers. When appropriate, treatment is enclomiphene or the enclomiphene plus tadalafil tablet. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Myth vs fact

Myth: “If my LDL cholesterol is normal, I do not need to think about inflammation and heart disease.”

Fact: Risk-enhancing factors (including hsCRP and certain inflammatory conditions) can clarify risk even when standard lipid goals look acceptable, which is why they are included in modern prevention frameworks. ^[1]

Myth: “High-sensitivity C-reactive protein tells me exactly where inflammation is coming from.”

Fact: hsCRP is sensitive but not specific. A high value can reflect infection, injury, or chronic disease. Confirm persistence and interpret it with your full clinical picture. ^[2]

Myth: “I can take an anti-inflammatory supplement and skip lifestyle changes.”

Fact: Human trials support some supplement effects on CRP, but prevention still starts with exercise, weight management, and diet quality. ^{[1] [4]}

Myth: “Lipoprotein(a) is just another cholesterol number that will change if I eat better.”

Fact: Lipoprotein(a) is largely genetic. It is mainly a risk clarifier, not a lifestyle scorecard, so many men only need to test it once. ^[3]

Bottom line

Inflammation-related heart risk is measurable and partly modifiable, but finding it means looking beyond the standard lipid panel. For many men, adding hsCRP, lipoprotein(a), ApoB-aware lipid interpretation, and metabolic markers helps explain risk that cholesterol alone misses. Start with lifestyle basics you can repeat, then use clinician-guided medication and targeted adjuncts when lab patterns stay elevated.

References

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. PMID: 30879355
2. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. PMID: 12551878
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188. PMID: 31504418
4. Li K, Huang T, Zheng J, et al. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis. PLoS One. 2014;9:e88103. PMID: 24505395
5. Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017;6. PMID: 29065496
6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74. PMID: 12490960
7. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-79. PMID: 12235168
8. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582:97-105. PMID: 18053812
9. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol. 2013;10:219-30. PMID: 23380975
10. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014;140:774-815. PMID: 24417575
11. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46:183-196. PMID: 28228278
12. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-436. PMID: 23265341
13. Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am Fam Physician. 2015;92:1004-11. PMID: 26760415
14. May JE, Marques MB, Reddy VVB, et al. Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. Cleve Clin J Med. 2019;86:167-172. PMID: 30849034
15. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
16. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
17. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. PMID: 18997196